Market Research Logo

Global Hemophilia Market: Industry Analysis & Outlook (2018-2022)

Global Hemophilia Market: Industry Analysis & Outlook (2018-2022)

The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion of the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes abnormal bleeding with poor clotting. It is classified into hemophilia A, hemophilia B, hemophilia C, and hemophilia with inhibitors.

Treatment for hemophilia is done via replacement therapy, prophylactic therapy, on-demand therapy, gene therapy and many others. Gene therapy is being regarded as an attractive option for treatment of hemophilia. By the year 2030, the pharmaceutical companies are expected to launch their gene therapy treatment for hemophilia, and this might affect the market dynamics at large.

The growth factors of the hemophilia market include increased focus on prophylactic treatment, growing market for FVIII, increasing diagnosis rate, and increasing healthcare expenditure. Major trends of the market include development of novel hemophilia treatment, shifting to extended half-life therapies and growing popularity of gene therapy. Further, growth prospects are hindered by high cost of therapy and consumer’s reluctance in switching to new therapy options.

The report offers an in-depth analysis of the global hemophilia market. It covers the global as well as regional aspect of the market. The top notch players in the market exhibit a very close competitive landscape. The report profiles Pfizer Inc., Bayer Group, Shire PLC, and Novo Nordisk.


1. Market Overview
1.1 Hemophilia
1.2 Types of Hemophilia
1.2 Types of Hemophilia
Table 1: Types of Hemophilia
1.3 Signs & Symptoms
Table 2: Signs & Symptoms of Hemophilia
1.4 Diagnosis & Treatment
2. Global Market Analysis
2.1 Global Hemophilia Market by Value
Table 3: Global Hemophilia Market by Value (2013-2017)
2.2 Global Hemophilia Market Forecast by Value
Table 4: Global Hemophilia Market Forecast by Value (2018-2022)
2.3 Global Hemophilia Market by Treatment Regimen
Table 5: Global Hemophilia Market by Treatment Regimen (2017)
2.4 Global Hemophilia Market by Type
Table 6: Global Hemophilia Market by Type (2017)
2.4.1 Global Hemophilia A Market Forecast by Value
Table 7: Global Hemophilia A Market Forecast by Value (2017-2022)
2.4.2 Global Hemophilia A Market by Severity
Table 8: Global Hemophilia A Market by Severity (2017)
2.4.3 Global Hemophilia A Market by Treatment Regimen
Table 9: Global Hemophilia A Market by Treatment Regimen (2017/2022)
2.4.4 Global Hemophilia with Inhibitors Market Forecast by Value
Table 10: Global Hemophilia With Inhibitors Market Forecast by Value (2017-2022)
2.4.5 Global Hemophilia B Market Forecast by Value
Table 11: Global Hemophilia B Market Forecast by Value (2017-2022)
2.4.6 Global Hemophilia B Market by Severity
Table 12: Global Hemophilia B Market by Severity (2017)
2.4.7 Global Hemophilia B Market by Treatment Regimen
Table 13: Global Hemophilia B Market by Treatment Regimen (2017/2022)
3. Regional Market Analysis
3.1 The US
3.1.1 The US Hemophilia Market by Value
Table 14: The US Hemophilia Market by Value (2013-2017)
3.1.2 The US Hemophilia Market Forecast by Value
Table 15: The US Hemophilia Market Forecast by Value (2018-2022)
3.1.3 The US Hemophilia Market by Type
Table 16: The US Hemophilia Market by Type (2017)
3.1.4 The US Hemophilia A Market Forecast by Value
Table 17: The US Hemophilia A Market Forecast by Value (2017-2022)
3.1.5 The US Hemophilia A Market by Products
Table 18: The US Hemophilia A Market by Products (2017)
3.1.6 The US Hemophilia A Market-Treated Patient Volume Forecast
Table 19: The US Hemophilia A Market-Treated Patient Volume Forecast (2017-2022)
3.1.7 The US Hemophilia A Market-Severe Patients on Prophylactic Therapy
Table 20: The US Hemophilia A Market-Severe Patients on Prophylactic Therapy (2017-2022)
3.1.8 The US Hemophilia A Market-Severe Patients on On-Demand Therapy
Table 21: The US Hemophilia A Market-Severe Patients on On-Demand Therapy (2017-2022)
3.1.9 The US Hemophilia A Market-Mild to Moderate Patients on Prophylaxis Therapy
Table 22: The US Hemophilia A Market-Mild to Moderate Patients on Prophylaxis Therapy (2017-2022)
3.1.10 The US Hemophilia A Market-Mild to Moderate Patients on On-Demand Therapy
Table 23: The US Hemophilia A Market-Mild to Moderate Patients on On-Demand Therapy (2017-2022)
3.1.11 The US Hemophilia B Market Forecast by Value
Table 24: The US Hemophilia B Market Forecast by Value (2017-2022)
3.1.12 The US Hemophilia B Market- Treated Patients Volume Forecast
Table 25: The US Hemophilia B Market- Treated Patients Volume Forecast (2017-2022)
3.1.13 The US Hemophilia B Market- Severe Patients on Prophylaxis Therapy
Table 26: The US Hemophilia B Market- Severe Patients on Prophylaxis Therapy (2017-2022)
3.1.13 The US Hemophilia B Market- Severe Patients on Prophylaxis Therapy
Table 26: The US Hemophilia B Market- Severe Patients on Prophylaxis Therapy (2017-2022)
3.1.14 The US Hemophilia B Market- Severe Patients on On-Demand Therapy
Table 27: The US Hemophilia B Market- Severe Patients on On-Demand Therapy (2017-2022)
3.1.15 The US Hemophilia B Market- Mild to Moderate Patients on Prophylaxis Therapy
Table 28: The US Hemophilia B Market- Mild to Moderate Patients on Prophylaxis Therapy (2017-2022)
3.1.16 The US Hemophilia B Market- Mild to Moderate Patients on On-Demand Therapy
Table 29: The US Hemophilia B Market- Mild to Moderate Patients on On-Demand Therapy (2017-2022)
3.2 Europe
3.2.1 Europe’s Hemophilia Market- Patient Volume Forecast
Table 30: Europe’s Hemophilia Market- Patient Volume Forecast (2017-2022)
3.2.2 Europe’s Hemophilia A Market- Patient Volume Forecast
Table 31: Europe’s Hemophilia A Market- Patient Volume Forecast (2017-2022)
3.2.3 Europe’s Hemophilia B Market- Patient Volume Forecast
Table 32: Europe’s Hemophilia B Market- Patient Volume Forecast (2017-2022)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increased Focus on Prophylactic Treatment
Table 33: Market Share of Hemophilia A Patients on Prophylaxis in the US (Q1-2015-Q1-2017)
Table 34: Market Share of Hemophilia B Patients on Prophylaxis in the US (Q1-2015-Q1-2017)
4.1.2 Increasing Diagnosis Rate
Table 35: Global Identified Hemophilia Patients Volume (2010-2017)
4.1.3 Rising Healthcare Expenditure
Table 36: Global Healthcare Expenditure (2013-2017)
4.2 Key Trends & Development
4.2.1 Shifting to Extended Half Life Therapies
Table 37: Extended Half Life Products (2017)
4.2.2 Development of Novel Hemophilia Treatments
Table 38: Development of New Novel Hemophilia Treatments (2017)
4.2.3 Popularity of Gene Therapy
Table 39: Hemophilia Gene Therapy Candidates (2017/2018)
4.3 Challenges
4.3.1 High Cost of Treatment
4.3.2 Reluctance to Switch to New Therapies
5. Competitive Landscape
5.1 Global Hemophilia Market
5.1.1 Revenue and Market Cap Comparison
Table 40: Revenue & Market Cap Comparison by Key Players (2017)
5.2 Global Hemophilia A Market
5.2.1 Global Hemophilia A Market Share by Company
Table 41: Global Hemophilia A Market Share by Company (2017)
5.2.2 Global Hemophilia A Factor VIII Products Market Share by Company
Table 42: Global Hemophilia A Factor VIII Products Market Share by Company (2022/2030)
5.2.3 Global Hemophilia A FVIII Gene Therapy Market Share Forecast
Table 43: Global Hemophilia A FVIII Gene Therapy Market Share Forecast (2030)
5.3 Global Hemophilia B Market
5.3.1 Global Hemophilia B Market Share by Company
Table 44: Global Hemophilia B Market Share by Company (2017)
5.3.2 Global Hemophilia B Factor IX Products Market Share Forecast
Table 45: Global Hemophilia B Factor IX Products Market Share Forecast (2022/2030)
5.3.3 Global Hemophilia B Factor IX Gene Therapy Market Share Forecast
Table 46: Global Hemophilia B Factor IX Gene Therapy Market Share Forecast (2030)
6. Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Overview
Table 47: Major Business Segme
nts of the Pfizer Inc. (2017)
Table 48: Pfizer Inc.'s Revenue Share by Major Business Segment (2017)
6.1.2 Financial Overview
Table 49: Pfizer Inc.’s Revenue and Net Income (2013-2017)
6.1.3 Business Strategies
Table 50: Pfizer Inc. R&D Expenses (2015-2017)
6.2 Bayer Group
6.2.1 Business Overview
Table 51: Bayer Group’s Net Sales Share by Business Segments (2016)
6.2.2 Financial Overview
Table 52: Bayer Group’s Net Sales and Net Income (2012-2016)
6.2.3 Business Strategies
Table 53: Major Products Developed by Bayer Group (2017/2018)
6.3 Shire PLC
6.3.1 Business Overview
Table 54: Shire PLC’s Revenue Share by Franchise (2017)
6.3.2 Financial Overview
Table 55: Shire PLC’s Revenue and Net Income (2013-2017)
6.3.3 Business Strategies
Table 56: Shire PLC’s Major Product Approvals & Launches (2017)
6.4 Novo Nordisk
6.4.1 Business Overview
Table 57: Novo Nordisk’s Net Sales Share by Business Segments (2017)
6.4.2 Financial Overview
Table 58: Novo Nordisk’s Net Sales and Net Profit (2013-2017)
6.4.3 Business Strategies
Table 59: Novo Nordisk’s Research and Development (2015-2017)
Table 60: Novo Nordisk’s Product Pipeline (2017)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report